Frailty score, sarcopenia, and myosteatosis: Stratifying risk and outcomes in non-transplant eligible patients with multiple myeloma treated with daratumumab-based dose-adjusted combination therapies
Multiple myeloma (MM) predominantly affects older patients, and the management of this population remains particularly challenging. Older patients with newly diagnosed multiple myeloma (NDMM) represent a clinically heterogeneous population in whom chronological age alone inadequately reflects treatment tolerance and prognosis. Frailty and body composition abnormalities are increasingly recognized as relevant determinants of outcomes in non–transplant-eligible patients [1,2]. While sarcopenia has been associated with poor survival across several solid malignancies, its prognostic role inMM remains controversial [3].
Authors
- Marco Ravanelli (ORCID: https://orcid.org/0000-0002-4841-2771)
- Rossella Ribolla
- Nicola Bianchetti
- Chiara Bottelli (ORCID: https://orcid.org/0000-0003-1062-950X)
- Angelo Belotti (ORCID: https://orcid.org/0000-0002-0617-3127)
- Daniele Avenoso (ORCID: https://orcid.org/0000-0003-4218-4170)
- Luigi Grazioli (ORCID: https://orcid.org/0000-0002-2345-1571)
- Claudia Crippa
- Alessandra Tucci (ORCID: https://orcid.org/0000-0003-3052-7463)
- Barbara Frittoli (ORCID: https://orcid.org/0000-0002-9647-1063)
- Teresa Falcone
- Samantha Ferrari
- Sofia Terlizzi
- Eleonora Vietti
Institutions
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Brescia (IT)
Publication Details
- Journal
- Journal of Geriatric Oncology
- Published
- 2026-10-15
- DOI
- https://doi.org/10.1016/j.jgo.2026.104640
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00